Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Dovitinib for Imatinib/Sumitinib-failed Gastrointestinal Stromal Tumors (GIST)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Yoon-Koo Kang, Asan Medical Center
ClinicalTrials.gov Identifier:
NCT01440959
First received: September 8, 2011
Last updated: January 13, 2014
Last verified: January 2014
Results First Received: November 12, 2013  
Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Gastrointestinal Stromal Tumors
Intervention: Drug: dovitinib

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Between September 2011 and April 2012, a total of 30 patients with metastatic and/or unresectable GISTs who had treatment failure with imatinib and sunitinib were enroled in Asan Medical Center, Seoul, Korea.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
There are no specific approaches between enrollment and treatment.

Reporting Groups
  Description
TKI258 dovitinib : TKI258 at 500 mg/day on a 5 days on/2 days off dosing schedule

Participant Flow:   Overall Study
    TKI258  
STARTED     30  
COMPLETED     30  
NOT COMPLETED     0  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
TKI258 dovitinib : TKI258 at 500 mg/day on a 5 days on/2 days off dosing schedule

Baseline Measures
    TKI258  
Number of Participants  
[units: participants]
  30  
Age  
[units: participants]
 
<=18 years     0  
Between 18 and 65 years     24  
>=65 years     6  
Age  
[units: years]
Mean ± Standard Deviation
  56.5  ± 10.4  
Gender  
[units: participants]
 
Female     9  
Male     21  
Region of Enrollment  
[units: participants]
 
Korea, Republic of     30  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Disease Control Rate (DCR; OR + Stable Disease)   [ Time Frame: Up to 24 weeks ]

2.  Secondary:   Overall Response Rate Using Both CT and PET Scans   [ Time Frame: Up to 24 weeks ]

3.  Secondary:   Number of Participants With Adverse Events   [ Time Frame: Monitoring of adverse events will be continued for at least 28 days following the last dose of study treatment, up to 3 year. ]

4.  Secondary:   Progression-free Survival   [ Time Frame: Up to 3 years ]

5.  Secondary:   Overall Survival   [ Time Frame: Up to 3 years ]

6.  Secondary:   Efficacy According to the Primary Mutation Type   [ Time Frame: Up to 24weeks ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.   Safety Issue:   No

7.  Secondary:   Efficacy According to the Concentrations of Circulating Growth Factors   [ Time Frame: Up to 24weeks ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.   Safety Issue:   No


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information